Welcome to our dedicated page for Neximmune news (Ticker: NEXI), a resource for investors and traders seeking the latest updates and insights on Neximmune stock.
NexImmune, Inc. (Nasdaq: NEXI) pioneers next-generation immunotherapies using its proprietary AIM™ technology to direct targeted immune responses against cancer and autoimmune diseases. This page provides centralized access to all official company updates, offering stakeholders timely insights into developments shaping the future of T cell-based therapies.
Investors and researchers will find verified updates on clinical trial progress, including NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. Track strategic financial decisions like the 2023 reverse stock split and operational adjustments, alongside research collaborations with institutions like Yale University exploring diabetes applications.
All content is curated for clarity and compliance, avoiding speculation while maintaining accessibility for both casual observers and experienced biotech analysts. Bookmark this page to monitor how NexImmune's AIM™ nanoparticle platform continues to redefine immunotherapy approaches across multiple disease areas.
NexImmune (Nasdaq: NEXI) has announced a collaboration with Yale University’s Department of Immunobiology to explore the regulation of autoimmune diabetes using its innovative artificial antigen presenting cells (AIM INJ). This collaboration aims to develop therapies targeting auto-reactive T cells that are responsible for Type 1 diabetes. Dr. Kevan Herold will lead the research, highlighting the potential for NexImmune’s technology to transform treatment for this chronic condition.
NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced it will report second-quarter financial results and provide a corporate update on August 9, 2021, after market close. The announcement highlights NexImmune's proprietary AIM™ nanoparticle technology, which directs T cell-mediated immune responses to treat conditions such as relapsed AML and multiple myeloma. The company is advancing its lead programs, NEXI-001 and NEXI-002, through clinical trials. Investors can access the release under the investor section of NexImmune's website.
NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced key leadership appointments, including Dr. Jack A. Ragheb as Senior Vice President, Translational Science, and Matt Schiller as Head of Business Development. Dr. Ragheb's extensive experience in cell therapy and immunology will support clinical development efforts, particularly for the AIM-nanoparticle technology. Mr. Schiller will focus on forming strategic partnerships to expand the company's technology into oncology and beyond. NexImmune's lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for relapsed AML and multiple myeloma.
NexImmune, Inc. (Nasdaq: NEXI) announced that Scott Carmer, CEO, will present at the virtual 2021 Human Health Innovation Conference on June 22, 2021, at 9:20 a.m. ET. The presentation will be available via live webcast and later as a replay on NexImmune's website. The company, focused on innovative immunotherapy, utilizes its proprietary AIM™ nanoparticle technology to generate targeted immune responses with decreased off-target effects. Its lead programs, NEXI-001 and NEXI-002, are in clinical trials for relapsed AML post-stem cell transplant and refractory multiple myeloma.
NexImmune, Inc. (Nasdaq: NEXI) has established a Scientific Advisory Board (SAB) consisting of prominent experts in immuno-oncology and T cell biology. This new board will provide guidance for NexImmune's research and clinical activities leveraging their AIM nanotechnology platform. The SAB includes leaders from renowned institutions such as NYU Langone Health and Yale University. The company’s lead programs, NEXI-001 and NEXI-002, are currently in Phase 1/2 clinical trials targeting relapsed AML and refractory multiple myeloma. This strategic move aims to enhance NexImmune's clinical development and pipeline advancement.
NexImmune (Nasdaq: NEXI), a clinical-stage biotechnology company, announced the presentation of data from its Phase 1/2 study of NEXI-001 at the ASCO 2021 Annual Meeting, scheduled for June 4-8, 2021. The clinical trial focuses on the treatment of relapsed acute myeloid leukemia (AML) post-hematopoietic cell transplantation. The study aims to utilize NexImmune's proprietary AIM nanoparticle technology to enhance the immune response.
NexImmune, Inc. (Nasdaq: NEXI) reported Q1 2021 results, highlighting a robust cash position following a $126M IPO in February 2021. The company is advancing NEXI-001 and NEXI-002, both in Phase 1/2 clinical trials, with preliminary data expected at upcoming scientific conferences. Cash and equivalents reached $118.1M, supporting operations through mid-2022. R&D expenses rose to $6.0M, largely due to clinical trial costs, while general and administrative expenses increased to $4.1M. The net loss for the quarter was $8.5M, or $0.71 per share, up from $6.3M year-over-year.
NexImmune, a clinical-stage biotechnology company focused on innovative immunotherapy, announced the appointment of Chad Rubin as Senior Vice President, Corporate Affairs. Previously at Solebury Trout, Rubin brings over 20 years of experience in biotech investor relations. His role will encompass corporate communications and investor relations, enhancing NexImmune's strategic outreach as it transitions to a public, clinically-driven entity. The company is advancing its proprietary AIM™ nanoparticle technology, with clinical trials for two lead programs, NEXI-001 and NEXI-002, targeting difficult diseases like cancer.
NexImmune, Inc. (NEXI) reported its 2020 financial results, highlighting significant advancements in its clinical trials and corporate structure. Notably, the company completed a successful $126M IPO in February 2021, which positions it to fund operations through mid-2022. Both lead programs, NEXI-001 and NEXI-002, entered Phase 1/2 trials, with early safety data presented at the ASH annual meeting. R&D expenses increased to $17.8M, while net loss escalated to $29.9M, up from $20.5M in 2019. NexImmune aims to enhance its AIM ACT product pipeline targeting solid tumors while bolstering its management team.
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company, announced that CEO Scott Carmer will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. Eastern time.
The presentation will be available via live webcast, and a replay will be accessible on the NexImmune website post-event. The company focuses on developing innovative immunotherapy designed to direct antigen-specific T cells for a targeted immune response, promoting a potent and durable reaction mimicking natural biology.
